abstract |
The present disclosure relates to antisense oligonucleotides, which target alpha-synuclein (SNCA) transcription in a cell leading to reduced SNCA protein expression. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, for example a neurological disorder such as a synucleinopathy. |